Zhang Wengang, Liu Yonglan, Jang Hyunbum, Nussinov Ruth
Cancer Innovation Laboratory, National Cancer Institute, Frederick, MD 21702, U.S.A.
Computational Structural Biology Section, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, U.S.A.
bioRxiv. 2023 Aug 17:2023.08.16.553605. doi: 10.1101/2023.08.16.553605.
Dysregulation of cyclin-dependent kinases (CDKs) impacts cell proliferation, driving cancer. Here, we ask why the cyclin-D/CDK4 complex governs cell cycle progression through the longer G1 phase, whereas cyclin-E/CDK2 regulates the short G1/S phase transition. We consider the experimentally established high-level bursting of cyclin-E, and sustained duration of elevated cyclin-D expression in the cell, available experimental cellular and structural data, and comprehensive explicit solvent molecular dynamics simulations to provide the mechanistic foundation of the distinct activation scenarios of cyclin-D/CDK4 and cyclin-E/CDK2 in the G1 phase and G1/S transition of the cell cycle, respectively. These lead us to propose slower activation of cyclin-D/CDK4 and rapid activation of cyclin-E/CDK2. Importantly, we determine the mechanisms through which this occurs, offering innovative CDK4 drug design considerations. Our insightful mechanistic work addresses the compelling cell cycle regulation question and illuminates the distinct activation speeds in the G1 versus G1/S phases, which are crucial for cell function.
细胞周期蛋白依赖性激酶(CDK)的失调会影响细胞增殖,进而引发癌症。在此,我们探讨为何细胞周期蛋白D/CDK4复合物通过较长的G1期来调控细胞周期进程,而细胞周期蛋白E/CDK2则调节较短的G1/S期转换。我们考虑了实验确定的细胞周期蛋白E的高水平爆发、细胞中细胞周期蛋白D表达升高的持续时间、现有的实验细胞和结构数据,以及全面的显式溶剂分子动力学模拟,以分别为细胞周期的G1期和G1/S转换中细胞周期蛋白D/CDK4和细胞周期蛋白E/CDK2不同的激活情况提供机制基础。这些使我们提出细胞周期蛋白D/CDK4激活较慢而细胞周期蛋白E/CDK2激活较快的观点。重要的是,我们确定了其发生的机制,为CDK4药物设计提供了创新的考虑因素。我们富有洞察力的机制研究解决了引人关注的细胞周期调控问题,并阐明了G1期与G1/S期不同的激活速度,这对细胞功能至关重要。